Cholesterol removal from plaques and elimination from the body: change in paradigm to reduce risk for heart disease

References

• Mihaylova B, Emberson J, Blackwell L et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Cholesterol Treatment Trialists’ (CTT) Collaborators. Lancet 380(9841), 581–590 (2012). •• Direct demonstration of residual risk despite reaching target low-density lipoprotein-cholesterol (LDL-C) levels with statin therapy.
   Google Scholar
• Kruth HS. Sequestration of aggregated low-density lipoproteins by macrophages. Curr. Opin. Lipidol. 13(5), 483–488 (2002).
   Google Scholar
• Kruth HS, Jones NL, Huang W et al. Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. J. Biol. Chem. 280(3), 2352–2360 (2005).
   Google Scholar
• Kruth HS, Huang W, Ishii I et al. Macrophage foam cell formation with native low density lipoprotein. J. Biol. Chem. 277(37), 34573–34580 (2002).
   Google Scholar
• Tabas I. Cholesterol and phospholipid metabolism in macrophages. Biochim. Biophys. Acta 1529, 164–174 (2000).
   Google Scholar
• Brown MS, Ho YK, Goldstein JL The cholesteryl ester cycle in macrophage foam cells. Continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters. J. Biol. Chem. 255(19), 9344–9452 (1980).
   Google Scholar
• Rothblat GH, de la Llera-Moya M, Favari E et al. Cellular cholesterol flux studies: methodological considerations. Atherosclerosis 163(1), 1–8 (2002).
   Google Scholar
• Ishii I, Oka M, Katto N et al. Beta-VLDL-induced cholesterol ester deposition in macrophages may be regulated by neutral cholesterol esterase activity. Arterioscler. Thromb. 12, 1139–1145 (1992).
   Google Scholar
• Mathur SN, Field FJ, Megan MB et al. A defect in mobilization of cholesteryl esters in rabbit macrophages. Biochim. Biophys. Acta 834, 48–57 (1985).
   Google Scholar
• Yancey PG and St. Clair RW. Mechanism of the defect in cholesteryl ester clearance from macrophages of atherosclerosis susceptible White Carneau pigeons. J. Lipid Res. 35, 2114–2129 (1994).
   Google Scholar
• Crow JA, Middleton BL, Borazjani A, Hatfield MJ, Potter PM, Ross MK. Inhibition of carboxylesterase 1 is associated with cholesteryl ester retention in human THP-1 monocyte/ macrophages. Biochim. Biophys. Acta. 1781(10), 643–654 (2008).
   Google Scholar
• Zhao B, Song J, Chow WN et al. Macrophage-specific transgenic expression of cholesteryl ester hydrolase significantly reduces atherosclerosis and lesion necrosis in Ldlr mice. J. Clin. Invest. 117(10), 2983–2992 (2007). •• First study to demonstrate that increasing removal of cholesterol from macrophages without affecting plasma cholesterol levels is antiatherogenic.
   Google Scholar
• Bie J, Zhao B, Ghosh S. Atherosclerotic lesion progression is attenuated by reconstitution with bone marrow from macrophage-specific cholesteryl ester hydrolase transgenic mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 301(4), R967–R974 (2011).
   Google Scholar
• Ghosh S, Zhao B, Bie J, Song J. Role of choelsteryl ester hydrolases in atherosclerosis. Clin. Lipidol. 4(5), 573–585 (2009).
   Google Scholar
• Ghosh S, Zhao B, Bie J, Song J. Macrophage cholesteryl ester mobilization and atherosclerosis. Vascul. Pharmacol. 52(1–2), 1–10 (2010). •• Detailed review of macrophage cholesteryl ester hydrolases.
   Google Scholar
• Ghosh S. Macrophage cholesterol homeostasis and metabolic diseases: critical role of cholesteryl ester mobilization. Expert Rev. Cardiovasc. Ther. 9(3), 329–340 (2011).
   Google Scholar
• Ghosh S. Early steps in reverse cholesterol transport: cholesteryl ester hydrolase and other hydrolases. Curr. Opin. Endocrinol. Diabetes Obes. 19(2), 136–141 (2012).
   Google Scholar
• Westerterp M, Murphy AJ, Wang M et al. Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice. Circ. Res. 112(11), 1456–1465 (2013).
   Google Scholar
• Rubin EM, Krauss RM, Spangler EA et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353, 265–267 (1991).
   Google Scholar
• Duverger N, Kruth H, Emmanuel F et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 94, 713–717 (1996).
   Google Scholar
• DiDonato JA, Huang Y, Aulak KS et al. Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma. Circulation 128, 1644–1655 (2013).
   Google Scholar
• Huang Y, DiDonato JA, Levison BS et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat. Med. 20, 193–203 (2014).
   Google Scholar
• Hewing B, Parathath S, Barrett T et al. Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 34, 779–789 (2014).
   Google Scholar
• Shao B, Tang C, Sinha A et al. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced HDL oxidation by myeloperoxidase. Circ. Res. 114(11), 1733–1742 (2014).
   Google Scholar
• Haraguchi Y, Toh R, Hasokawa M et al. Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease. Atherosclerosis 234, 288–294 (2014).
   Google Scholar
• Tabas I, Wang Y. Emerging roles of mitochondria ROS in atherosclerotic lesions: causation or association? J. Atheroscler. Thromb. 21(5), 381–390 (2014).
   Google Scholar
• Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255–2267 (2011). • Increasing hdl-c does not provide any additional benefit over statin therapy.
   Google Scholar
• Song WL, FitzGerald GA. Niacin, an old drug with a new twist. J. Lipid. Res. 54, 2586–2594, 2013.
   Google Scholar
• Barter PJ, Caulfield M, Eriksson M et al. ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007).
   Google Scholar
• Nicholls SJ, Tuzcu EM, Brennan DM et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 118, 2506–2514 (2008). •• Lack of beneficial effects of raising hdl-c by cholesteryl ester transfer protein inhibition.
   Google Scholar
• Larach DB, Degoma EM, Rader DJ. Targeting high density lipoproteins in the prevention of cardiovascular disease? Curr. Cardiol. Rep. 14, 684–691 (2012). •• Importance of the change in focus from cholesterol-to-cholesterol flux.
   Google Scholar
• Friedman M, Byers SO, Rosenman RH. Resolution of aortic atherosclerotic infiltration in the rabbit by phosphatide infusion. Proc. Soc. Exp. Biol. Med. 95, 586–588 (1957). •• First study to demonstrate plaque regression.
   Google Scholar
• Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 85, 1234–1241 (1990).
   Google Scholar
• Shah PK, Yano J, Reyes O et al. High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation 103, 3047–3050 (2001).
   Google Scholar
• Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290, 2292–2300 (2003). •• First clinical study to demonstrate plaque regression.
   Google Scholar
• Tardif JC, Grégoire J, L’Allier PL et al. Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297, 1675–1682 (2007).
   Google Scholar
• Turner S, Voogt J, Davidson M et al. Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion. J. Am. Heart Assoc. 1 , e001826 (2012).
   Google Scholar
• van der Veen JN, van Dijk TH, Vrins CL et al. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J. Biol. Chem. 284, 19211–19219 (2009).
   Google Scholar
• Jakulj L, Besseling J, Stroes ES, Groen AK. Intestinal cholesterol secretion: future clinical implications. Neth. J. Med. 71, 459–465 (2013). • Important role of transintestinal cholesterol efflux/excretion in cholesterol elimination from the body.
   Google Scholar
• Le May C, Berger JM, Lespine A et al. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arterioscler. Thromb. Vasc. Biol. 33(7), 1484–1493 (2013).
   Google Scholar
• Vrins CL, Ottenhoff R, van den Oever K et al. Trans-intestinal cholesterol efflux is not mediated through high density lipoprotein. J. Lipid. Res. 53, 2017–2023 (2012).
   Google Scholar
• Marshall SM, Kelley KL, Davis MA et al. Reduction of VLDL secretion decreases cholesterol excretion in niemannpick C1-like 1 hepatic transgenic mice. PLoS ONE 9(1), e84418 doi 10.1371 (2014).
   Google Scholar
• Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl. Acad. Sci. USA 96(20), 11041–11048 (1999). • Mechanisms involved in cholesterol sensing and regulation of gene expression.
   Google Scholar
• Sniderman AD, Qi Y, Ma CI et al. Hepatic cholesterol homeostasis: is the low-density lipoprotein pathway a regulatory or a shunt pathway? Arterioscler. Thromb. Vasc. Biol. 33(11), 2481–2490 (2013). •• First study to demonstrate fate of LDL-C in the liver.
   Google Scholar
• Kozarsky KF, Donahee MH, Rigotti A et al. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 387(6631), 414–417 (1997).
   Google Scholar
• Yuan Q, Bie J, Wang J et al. Cooperation between hepatic cholesteryl ester hydrolase and scavenger receptor BI for hydrolysis of HDL-CE. J. Lipid. Res. 54(11), 3078–3084 (2013). •• First study to report cooperation between SR-BI and intracellular cholesteryl ester hydrolase.
   Google Scholar
• Bie J, Wang J, Yuan Q et al. Liver-specific transgenic expression of cholesteryl ester hydrolase reduces atherosclerosis in Ldlr-/- mice. J. Lipid. Res. 55(4), 729–738 (2014). •• First study to demonstrate antiatherogenic role of hepatic cholesteryl ester hydrolase.
   Google Scholar
• Bie J, Wang J, Marqueen KE et al. Liver-specific cholesteryl ester hydrolase deficiency attenuates sterol elimination in the feces and increases atherosclerosis in ldlr-/- mice. Arterioscler. Thromb. Vasc. Biol. 33(8), 1795–1802 (2013).
   Google Scholar
• Rodriguez-Agudo D, Ren S, Wong E et al. Intracellular cholesterol transporter StarD4 binds free cholesterol and increases cholesteryl ester formation. J. Lipid. Res. 49(7), 1409–1419 (2008).
   Google Scholar
• Pandak WM, Ren S, Marques D et al. Transport of cholesterol into mitochondria is rate-limiting for bile acid synthesis via the alternative pathway in primary rat hepatocytes. J. Biol. Chem. 277(50), 48158–48164 (2002).
   Google Scholar
• Atshaves BP, McIntosh AL, Martin GG et al. Overexpression of sterol carrier protein-2 differentially alters hepatic cholesterol accumulation in cholesterol-fed mice. J. Lipid. Res. 50(7), 1429–1447 (2009).
   Google Scholar
• Lee P and Hegele RA. Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia. Expert Opin. Investig. Drugs 22(11), 1411–1423 (2013). • Clinical trials to evaluate PSCK9 inhibition based therapies.
   Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251, 351–364 (1984).
   Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251, 365–374 (1984). •• First studies to evaluate the role of bile acid sequesterants for cardiovascular disease.
   Google Scholar
• Soma MR, Donetti E, Parolini C et al. Recombinant apolipoprotein A-Imilano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ. Res. 76, 405–411 (1995).
   Google Scholar
• Tardif JC, Gregoire J, L’Allier PL et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297(15), 1675–1682 (2007).
   Google Scholar
• Tardy C, Goffinet M, Boubekeur N et al. CER-001, an HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDLreceptor deficient mice. Atherosclerosis 232(1), 110–118 (2014).
   Google Scholar